SXTP 60 DEGREES PHARMACEUTICALS INC

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference

WASHINGTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, announced today the webcast link and change of date for management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference in New York City, to Tuesday, September 9, 3:30 PM Eastern Time.

Dr. Geoff Dow, 60 Degrees Pharma CEO, will present live and management will conduct one-on-one meetings during the conference.

Event: H.C. Wainwright 27th Annual Global Investment Conference

Date: September 9, 2025

Time: 3:30 PM ET

Location: Lotte New York Palace Hotel

Webcast:

About 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018. ARAKODA is commercially available in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research and academic organizations in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at .

The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.

Media Contact:

Sheila A. Burke



(484) 667-6330

Investor Contact:

Patrick Gaynes



EN
03/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 60 DEGREES PHARMACEUTICALS INC

 PRESS RELEASE

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection...

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study Breakthrough Therapy Designation request has been submitted to FDACompany to request a Type B meeting with FDA in early 2026 to discuss requirements for a supplementary New Drug Application (sNDA)Results obtained using highest sensitivity test available; licensed by FDA for blood donation screeningRemaining enrolled patients will complete the study between January and October 2026Study intended to confirm the high cure rate for tafenoquin...

 PRESS RELEASE

60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical...

60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study Company engaged patients diagnosed with chronic babesiosis via social media in a nationwide naming competitionA $5K donation from the Company was split between ILADEF and GLA to recognize the winning nameB-FREE, a Phase 2 trial, will commence in early November and run for approximately 12 months WASHINGTON, Oct. 09, 2025 (GLOBE NEWSWIRE) --   (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne...

 PRESS RELEASE

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presenta...

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference WASHINGTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, announced today the webcast link and change of date for management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference in New York City, to Tuesday, September 9, 3:30 PM Eastern Time. Dr. Geoff Dow, 60 Degrees Pharma CEO, will ...

 PRESS RELEASE

60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual G...

60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference WASHINGTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, announced today it will participate in the H.C. Wainwright (HCW) 27th Annual Global Investment Conference at the Lotte New York Palace Hotel, September 8-10, 2025. Dr. Geoff Dow, CEO, will be presenting live on Wednesday, September 10, at 2:30 ET, and Company management will be conducting 1x1 mee...

 PRESS RELEASE

60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount S...

60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis 90-day trial measuring change in general fatigue in chronic babesiosis patientsEnrollment expected to commence Q4 2025 and to be completed by Q2 2026Site has clinical expertise in infectious disease trials and access to a robust patient population with tick-borne illness, including chronic babesiosisNo FDA-approved treatment exists for chronic babesiosis, a debilitating illness WASHINGTON, Aug. 19, 2025 (GLOBE NEWSWIRE...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch